Andrx, Schering Settle Claritin-D Patent Dispute

Law360, New York (October 24, 2003, 12:00 AM EDT) -- Andrx Corp. settled a patent dispute with Schering-Plough Corp. over Andrx's generic version of the Claritin-D 24-hour allergy medicine, the companies said Friday.

Andrx will receive a license to a patent for the drug from Schering-Plough, the company said. Andrx said that the lawsuit would be dismissed, but did not disclose financial terms of the settlement.

Andrx's generic Claritin-D 24 is marketed by Perrigo Company as an over-the-counter product used for the relief of symptoms of seasonal allergic rhinitis, commonly known as hay fever, the company...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.